A Comment on Metformin and COVID-19 with Regard to "Metformin Use Is Associated with a Decrease in the Risk of Hospitalization and Mortality in COVID-19 Patients with Diabetes: A Population-Based Study in Lombardy"

Abdallah Al-Salameh (1, 2) , Nicolas Wiernsperger (3) , Bertrand Cariou (4) , Jean-Daniel Lalau (1, 2)

1 CHU Amiens-Picardie
2 PERITOX - Périnatalité et Risques Toxiques - UMR INERIS_I 1
3 CarMeN - Cardiovasculaire, métabolisme, diabétologie et nutrition
4 ITX-lab - ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291

Mots clés: COVID-19/epidemiology; Diabetes Mellitus; Type 2/complications/drug therapy/epidemiology; Metformin/therapeutic use; Hospitalization; Humans; Hypoglycemic Agents/adverse effects; Retrospective Studies; SARS-CoV-2

Domaines: Médecine humaine et pathologie

Abdallah Al-Salameh, Nicolas Wiernsperger, Bertrand Cariou, Jean-Daniel Lalau. A Comment on Metformin and COVID-19 with Regard to "Metformin Use Is Associated with a Decrease in the Risk of Hospitalization and Mortality in COVID-19 Patients with Diabetes: A Population-Based Study in Lombardy". Diabetes, Obesity and Metabolism, 2022, 24 (9), pp.1888--1893. ⟨10.1111/dom.14746⟩. ⟨hal-03746083⟩